SG158143A1 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders - Google Patents

Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Info

Publication number: SG158143A1
Authority: SG; Singapore
Prior art keywords: proliferative; inflammatory disorders; neurological; treatment; compounds
Prior art date: 2004-12-20

Application number

SG200908383-3A

Other languages

English (en)

Inventor

Edmund Idris Graziani

Kevin Pong

Jerauld Skotnicki

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-20

Filing date

2005-12-15

Publication date

2010-01-29

2005-12-15 Application filed by Wyeth Corp filed Critical Wyeth Corp

2010-01-29 Publication of SG158143A1 publication Critical patent/SG158143A1/en

Links

208000027866 inflammatory disease Diseases 0.000 title abstract 2
230000002062 proliferating effect Effects 0.000 title abstract 2
230000000926 neurological effect Effects 0.000 title 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000012902 Nervous system disease Diseases 0.000 abstract 2
201000009030 Carcinoma Diseases 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000031481 Pathologic Constriction Diseases 0.000 abstract 1
208000009956 adenocarcinoma Diseases 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000003018 neuroregenerative effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG200908383-3A 2004-12-20 2005-12-15 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders SG158143A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63766604P	2004-12-20	2004-12-20

Publications (1)

Publication Number	Publication Date
SG158143A1 true SG158143A1 (en)	2010-01-29

Family

ID=36087657

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200908383-3A SG158143A1 (en)	2004-12-20	2005-12-15	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Country Status (26)

Country	Link
US (5)	US7276498B2 (de)
EP (1)	EP1828202B1 (de)
JP (1)	JP5094406B2 (de)
KR (1)	KR20070090913A (de)
CN (1)	CN101084227B (de)
AR (1)	AR052269A1 (de)
AT (1)	ATE549342T1 (de)
AU (1)	AU2005319454B2 (de)
BR (1)	BRPI0519495A2 (de)
CA (1)	CA2590155A1 (de)
CR (1)	CR9148A (de)
DK (1)	DK1828202T3 (de)
ES (1)	ES2380779T3 (de)
GT (1)	GT200500368A (de)
HN (1)	HN2005035605A (de)
IL (1)	IL183664A (de)
MX (1)	MX2007007408A (de)
NI (1)	NI200700157A (de)
NO (1)	NO20072664L (de)
NZ (1)	NZ574663A (de)
PE (1)	PE20060765A1 (de)
RU (1)	RU2394036C2 (de)
SG (1)	SG158143A1 (de)
TW (1)	TW200628152A (de)
UA (1)	UA94034C2 (de)
WO (1)	WO2006068932A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ537829A (en)	2002-07-30	2006-09-29	Wyeth Corp	Parenteral formulations containing a rapamycin hydroxyester
EP1720886A1 (de) *	2004-03-02	2006-11-15	Wyeth	Makrolide und verfahren zu deren herstellung
MXPA06014080A (es) *	2004-06-03	2007-02-15	Wyeth Corp	Agregado de genes biosinteticos para la produccion de un policetido complejo.
AU2005319454B2 (en) *	2004-12-20	2012-08-09	Wyeth	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
CA2590254A1 (en) *	2004-12-20	2006-06-29	Wyeth	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
BRPI0619592A2 (pt) *	2005-12-07	2016-09-06	Wyeth Corp	métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
US7622578B2 (en) *	2005-12-07	2009-11-24	Wyeth	Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
AR058282A1 (es) *	2005-12-07	2008-01-30	Wyeth Corp	Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
RU2008132779A (ru)	2006-03-07	2010-04-20	Вайет (Us)	Аналоги меридамицина для лечения нейродегенеративных заболеваний
WO2008022256A2 (en) *	2006-08-16	2008-02-21	Blagosklonny Mikhail V	Methods and compositions for preventing or treating age-related diseases
TW200824713A (en) *	2006-10-18	2008-06-16	Wyeth Corp	Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20100196355A1 (en) *	2007-01-29	2010-08-05	Wyeth	Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
KR101666228B1 (ko)	2007-09-28	2016-10-13	인트렉손 코포레이션	생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
WO2009100214A2 (en) *	2008-02-05	2009-08-13	The Johns Hopkins University	Induction of thyroid iodide-handling gene expression in human cancers
US20090209527A1 (en) *	2008-02-19	2009-08-20	Wyeth	Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
EP2365802B1 (de)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Mikrokapseln von rapamycin und deren verwendung zur behandlung von krebs
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
AU2010233073B2 (en)	2009-04-10	2014-07-31	Haiyan Qi	Novel anti-aging agents and methods to identify them
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
CA2794196A1 (en)	2010-03-23	2011-09-29	Intrexon Corporation	Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
ES2372077B2 (es) *	2010-06-24	2012-05-18	Universidad De Sevilla	Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (de) *	2010-10-29	2012-05-02	Fondazione Telethon	Autophagieregulierer und ihre Verwendungen beim der Behandlung von Kollagen-VI-gestörten Muskeldystrophien
SG10201600912SA (en)	2011-03-04	2016-03-30	Intrexon Corp	Vectors conditionally expressing protein
EP2589383A1 (de)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
US20150290176A1 (en)	2012-10-12	2015-10-15	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
ITMI20122065A1 (it) *	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
GB2538747B (en) *	2015-05-27	2022-04-13	Airbus Operations Ltd	A measuring apparatus for measuring properties of a surface
AU2016278040B2 (en)	2015-06-16	2019-07-04	Nanophagix LLC	Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
UY37343A (es)	2016-07-25	2018-02-28	Intrexon Corp	Control del fenotipo en plantas
CN110139933B (zh)	2016-11-09	2024-03-08	英特瑞克斯顿股份有限公司	共济蛋白表达构建体
EP3848065B1 (de)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung und zwischenschicht
WO2020076738A2 (en) *	2018-10-12	2020-04-16	Bellicum Pharmaceuticals, Inc	Protein-binding compounds
EP3880266B1 (de)	2018-11-14	2025-05-07	Lutonix, Inc.	Medizinische vorrichtung mit wirkstofffreisetzender beschichtung auf modifizierter vorrichtungsoberfläche
EP3914245A4 (de) *	2019-01-22	2022-08-24	Aeovian Pharmaceuticals, Inc.	Mtorc-1-modulatoren und verwendungen davon
WO2020209828A1 (en)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
EP4185590A2 (de) *	2020-07-21	2023-05-31	Aeovian Pharmaceuticals, Inc.	Mtorc1-modulatoren und verwendungen davon
CN114306330A (zh) *	2022-01-27	2022-04-12	中以海德人工智能药物研发股份有限公司	雷帕霉素在治疗或预防乙型肝炎中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1445742A1 (de)	1963-11-06	1968-12-19	Bayer Ag	Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de)	1965-06-21	1969-12-11	Bayer Ag	Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
GB1325047A (en)	1969-08-11	1973-08-01	Ciba Geigy Ag	Rifamycin compounds and processes for their manufacture
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en)	1973-04-05	1975-08-19	Lepetit Spa	3-formylrifamycin azines
US3905981A (en)	1973-10-12	1975-09-16	Research Corp	N-dealkylation of tertiary amines
US4127720A (en)	1977-09-21	1978-11-28	Bristol-Myers Company	Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja)	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
JPH05507915A (ja)	1990-06-11	1993-11-11	藤沢薬品工業株式会社	特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
DE4021404A1 (de)	1990-07-05	1992-01-09	Sandoz Ag	Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en) *	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
GB2249027A (en)	1990-10-23	1992-04-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds for hepatic failure
WO1992013862A1 (en)	1991-02-05	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Lactone compounds
US5604294A (en)	1991-09-05	1997-02-18	Luly; Jay R.	Macrocyclic immunomodulators
ES2179823T3 (es)	1991-09-05	2003-02-01	Abbott Lab	Inmunosupresor macrolido.
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US7279561B1 (en)	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
DE69435044T2 (de)	1993-04-23	2008-09-18	Wyeth	Rapamycin - Konjugate und Antikörper
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
US5525610A (en)	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
EP0833828B1 (de) *	1995-06-09	2002-11-20	Novartis AG	Rapamycinderivate
TW427904B (en) *	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5717092A (en)	1996-03-29	1998-02-10	Vertex Pharmaceuticals Inc.	Compounds with improved multi-drug resistance activity
US5780484A (en)	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en)	1998-06-03	2001-02-13	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
AU761083B2 (en)	1998-06-03	2003-05-29	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
BR9913052A (pt)	1998-08-17	2001-05-08	American Home Prod	Rapamicinas fotocilizadas
AU2478500A (en)	1998-12-08	2000-06-26	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
AU7124000A (en)	1999-09-09	2001-04-10	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6569867B2 (en)	1999-10-01	2003-05-27	Kosan Biosciences, Inc.	Polyketide derivatives
WO2001034816A1 (en)	1999-10-29	2001-05-17	Kosan Biosciences, Inc.	Rapamycin analogs
EP1282626A2 (de)	2000-05-17	2003-02-12	Kosan Biosciences, Inc.	Polyketid-derivate
MXPA04001523A (es)	2001-08-22	2004-05-31	Wyeth Corp	Dialdehidos de rapamicina.
BR0211986A (pt)	2001-08-22	2004-09-28	Wyeth Corp	29-enóis de rapamicina
CA2492153C (en)	2002-07-16	2012-05-08	Biotica Technology Limited	Production of polyketide fkbp-ligand analogues
DE102004049700B4 (de)	2004-10-12	2007-10-18	Aircabin Gmbh	Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
AU2005319454B2 (en)	2004-12-20	2012-08-09	Wyeth	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
CA2590254A1 (en) *	2004-12-20	2006-06-29	Wyeth	Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2008132779A (ru)	2006-03-07	2010-04-20	Вайет (Us)	Аналоги меридамицина для лечения нейродегенеративных заболеваний

2005
- 2005-12-15 AU AU2005319454A patent/AU2005319454B2/en not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519495-4A patent/BRPI0519495A2/pt not_active IP Right Cessation
- 2005-12-15 WO PCT/US2005/045551 patent/WO2006068932A2/en not_active Ceased
- 2005-12-15 ES ES05849447T patent/ES2380779T3/es not_active Expired - Lifetime
- 2005-12-15 NZ NZ574663A patent/NZ574663A/en not_active IP Right Cessation
- 2005-12-15 PE PE2005001466A patent/PE20060765A1/es not_active Application Discontinuation
- 2005-12-15 UA UAA200706849A patent/UA94034C2/ru unknown
- 2005-12-15 RU RU2007119584/04A patent/RU2394036C2/ru not_active IP Right Cessation
- 2005-12-15 MX MX2007007408A patent/MX2007007408A/es active IP Right Grant
- 2005-12-15 JP JP2007546925A patent/JP5094406B2/ja not_active Expired - Fee Related
- 2005-12-15 HN HN2005035605A patent/HN2005035605A/es unknown
- 2005-12-15 DK DK05849447.7T patent/DK1828202T3/da active
- 2005-12-15 TW TW094144448A patent/TW200628152A/zh unknown
- 2005-12-15 SG SG200908383-3A patent/SG158143A1/en unknown
- 2005-12-15 GT GT200500368A patent/GT200500368A/es unknown
- 2005-12-15 EP EP05849447A patent/EP1828202B1/de not_active Expired - Lifetime
- 2005-12-15 AR ARP050105290A patent/AR052269A1/es not_active Application Discontinuation
- 2005-12-15 US US11/300,839 patent/US7276498B2/en not_active Expired - Fee Related
- 2005-12-15 KR KR1020077013082A patent/KR20070090913A/ko not_active Ceased
- 2005-12-15 AT AT05849447T patent/ATE549342T1/de active
- 2005-12-15 CA CA002590155A patent/CA2590155A1/en not_active Abandoned
- 2005-12-15 CN CN2005800437154A patent/CN101084227B/zh not_active Expired - Fee Related
2007
- 2007-01-26 US US11/698,504 patent/US7560457B2/en not_active Expired - Fee Related
- 2007-05-24 CR CR9148A patent/CR9148A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072664A patent/NO20072664L/no not_active Application Discontinuation
- 2007-06-04 IL IL183664A patent/IL183664A/en not_active IP Right Cessation
- 2007-06-18 NI NI200700157A patent/NI200700157A/es unknown
- 2007-08-14 US US11/893,090 patent/US7470682B2/en not_active Expired - Fee Related
2008
- 2008-11-24 US US12/276,668 patent/US20090203682A1/en not_active Abandoned
2009
- 2009-06-09 US US12/481,211 patent/US7795252B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HN2005035605A (es)	2010-08-05
TW200628152A (en)	2006-08-16
DK1828202T3 (da)	2012-05-07
IL183664A0 (en)	2007-09-20
ES2380779T3 (es)	2012-05-18
JP5094406B2 (ja)	2012-12-12
NZ574663A (en)	2010-05-28
US20090239855A1 (en)	2009-09-24
EP1828202A2 (de)	2007-09-05
GT200500368A (es)	2006-07-13
US7470682B2 (en)	2008-12-30
US7795252B2 (en)	2010-09-14
US7276498B2 (en)	2007-10-02
ATE549342T1 (de)	2012-03-15
AU2005319454A1 (en)	2006-06-29
PE20060765A1 (es)	2006-10-02
US20090203682A1 (en)	2009-08-13
US20060135549A1 (en)	2006-06-22
AR052269A1 (es)	2007-03-07
RU2394036C2 (ru)	2010-07-10
KR20070090913A (ko)	2007-09-06
JP2008524240A (ja)	2008-07-10
CA2590155A1 (en)	2006-06-29
EP1828202B1 (de)	2012-03-14
BRPI0519495A2 (pt)	2009-02-03
HK1108442A1 (en)	2008-05-09
NO20072664L (no)	2007-06-25
IL183664A (en)	2012-06-28
WO2006068932A2 (en)	2006-06-29
WO2006068932A3 (en)	2006-10-19
RU2007119584A (ru)	2009-01-27
NI200700157A (es)	2008-04-21
AU2005319454B2 (en)	2012-08-09
CN101084227B (zh)	2011-11-16
MX2007007408A (es)	2007-07-12
US20070142423A1 (en)	2007-06-21
CR9148A (es)	2007-11-23
US20080004264A1 (en)	2008-01-03
US7560457B2 (en)	2009-07-14
CN101084227A (zh)	2007-12-05
UA94034C2 (ru)	2011-04-11

Publication	Publication Date	Title
SG158143A1 (en)	2010-01-29	Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
MX2007007409A (es)	2007-07-12	Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
GB2463833A (en)	2010-03-31	Methods and compositions for the treatment of neurological disorders
EA200601746A1 (ru)	2007-04-27	Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
EA200900662A1 (ru)	2009-12-30	Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
DE60329756D1 (de)	2009-12-03	Mitotische kinesin-hemmer
ATE521608T1 (de)	2011-09-15	Glucokinaseaktivatoren
TW200800976A (en)	2008-01-01	New compounds for the treatment of neurological, psychiatric or pain disorders
DK1450799T3 (da)	2007-03-19	Arylurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
MX2007002398A (es)	2007-05-15	Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2005013996A3 (en)	2005-06-09	2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
DE60231439D1 (de)	2009-04-16	Mitotische kinesinhemmer
DE60234278D1 (de)	2009-12-17	Mitotische kinesin-hemmer
ATE427759T1 (de)	2009-04-15	Behandlung von fettsucht und verbundenen erkrankungen
CY1112397T1 (el)	2015-12-09	Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
MY142988A (en)	2011-02-14	Novel aminobenzophenone compounds
MA29266B1 (fr)	2008-02-01	Traitement de tumeurs metastatiques
ECSP066986A (es)	2006-12-29	Beta-carbolinas utiles para tratar enfermedades inflamatorias
DE60233350D1 (de)	2009-09-24	IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
WO2006069253A3 (en)	2007-08-02	Trefoil factors and methods of treating proliferation disorders using same
WO2008042435A3 (en)	2008-07-24	Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
TW200706536A (en)	2007-02-16	Indole compounds
WO2009135939A3 (en)	2010-04-29	Pm02734 for use in the treatment of ewing' s sarcoma, osteosarcoma, rhabdomyosarcoma and medulloblastoma